SHSE:600276'
s ROE % Range Over the Past 10 Years
Min: 10.73 Med: 18.82 Max: 23.88
Current: 14.01
During the past 13 years, Jiangsu Hengrui Pharmaceuticals Co's highest ROE % was 23.88%. The lowest was 10.73%. And the median was 18.82%.
SHSE:600276's ROE % is ranked better than 76.31% of 933
companies
in the Drug Manufacturers industry
Industry Median: 5.89
vs SHSE:600276: 14.01
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Jiangsu Hengrui Pharmaceuticals Co ROE % Related Terms
Jiangsu Hengrui Pharmaceuticals Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's ROE % distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a ROE % of 14.62% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 22% below median its historical median of 18.82. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's ROE % has ranged from 10.73 to 23.88. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #221 out of 933 companies in the Drug Manufacturers industry, placing it in the top 23.7%.
Is Jiangsu Hengrui Pharmaceuticals Co's ROE % too high?
Jiangsu Hengrui Pharmaceuticals Co's current ROE % of 14.62% is 22% below median its 10-year median of 18.82. Over the past 10 years, this metric has ranged from a low of 10.73 to a high of 23.88. The Drug Manufacturers industry median ROE % is 5.89. Jiangsu Hengrui Pharmaceuticals Co's value of 14.62% is 148.2% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #221 out of 933 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #221 out of 933 companies for ROE %. This places Jiangsu Hengrui Pharmaceuticals Co in the top 24% of its industry — outperforming the majority of peers. The industry median ROE % is 5.89. Jiangsu Hengrui Pharmaceuticals Co's value of 14.62% is 148.2% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own ROE % has ranged from 10.73 to 23.88 over the past decade. While the company's 10-year median is 18.82 vs. the industry median of 5.89, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.89, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current ROE % of 14.62% is 148.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current ROE % is 14.62%, which is 22% below median its own 10-year median of 18.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.34, compared to a current price of ¥52.04 — trading 13.8% below its estimated fair value. The current ROE % is 14.62%, which is 22% below median its 10-year median of 18.82 and 148.2% above the Drug Manufacturers industry median of 5.89. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current ROE % is 14.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥52.04 is trading 13.8% below its estimated GF Value™ of ¥60.34.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SHSE:600276:
ROE %: 14.62% (22% below median its 10-year median of 18.82)
GF Value™: ¥60.34 vs. price of ¥52.04 (13.8% below fair value)
Industry Position: 148.2% above the Drug Manufacturers median (#221 of 933)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score
Get the complete analysis for SHSE:600276
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
